|
|
Article: NEUROCRINE BIOSCIENCES LAUNCHES BROAD PHASE III INSOMNIA PROGRAM.(Brief Article)
- Article from:
- BIOWORLD Today
- Article date:
- March 20, 2002
- Author:
CopyrightCOPYRIGHT 2002 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Aiming for a new drug application filing at the end of next year, Neurocrine Biosciences Inc. unveiled an eye-opening Phase III trial program that will include about 3,500 patients testing two formulations of the company's insomnia drug.
San Diego-based Neurocrine said it is starting three pivotal Phase III trials of the immediate-release form of NBI-34060 (having begun the first Phase III study late last year), and will conduct a total of five for that formulation. The company also expects to conduct three Phase III trials evaluating the modified-release version of the same drug.
Although details about the program previously were not disclosed, Paul ...